Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Up 11.9% in June

Bionano Genomics, Inc. (NASDAQ:BNGO) saw a significant growth in short interest in June. As of June 15th, there was short interest totalling 5,250,000 shares, a growth of 11.9% from the May 31st total of 4,690,000 shares. Based on an average daily volume of 1,310,000 shares, the short-interest ratio is currently 4.0 days. Approximately 7.7% of the company’s stock are short sold.

Bionano Genomics Price Performance

Shares of NASDAQ:BNGO remained flat at $0.57 during midday trading on Wednesday. The company had a trading volume of 1,992,671 shares, compared to its average volume of 1,483,865. The company has a current ratio of 1.46, a quick ratio of 1.13 and a debt-to-equity ratio of 0.04. Bionano Genomics has a twelve month low of $0.55 and a twelve month high of $6.76. The stock’s 50-day moving average is $0.90 and its two-hundred day moving average is $1.13.

Bionano Genomics (NASDAQ:BNGO) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter. Bionano Genomics had a negative return on equity of 129.31% and a negative net margin of 605.26%. The firm had revenue of $8.77 million for the quarter. As a group, sell-side analysts predict that Bionano Genomics will post -1.87 earnings per share for the current fiscal year.

Institutional Trading of Bionano Genomics

Several hedge funds and other institutional investors have recently modified their holdings of BNGO. Carret Asset Management LLC acquired a new position in Bionano Genomics during the fourth quarter worth $34,000. Virtu Financial LLC acquired a new position in Bionano Genomics during the first quarter worth $36,000. Headlands Technologies LLC acquired a new position in Bionano Genomics during the fourth quarter worth $72,000. Price T Rowe Associates Inc. MD increased its position in Bionano Genomics by 123.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after buying an additional 38,900 shares during the last quarter. Finally, Cantor Fitzgerald L. P. increased its position in Bionano Genomics by 22.2% during the fourth quarter. Cantor Fitzgerald L. P. now owns 55,000 shares of the company’s stock worth $104,000 after buying an additional 10,000 shares during the last quarter. 11.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Scotiabank reduced their target price on Bionano Genomics from $7.00 to $6.00 and set a “sector outperform” rating for the company in a report on Thursday, March 7th. BTIG Research reduced their target price on Bionano Genomics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Thursday, May 16th.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.